SCHEMBL15701289

SCHEMBL15701289

O=C(O)Cc1ccc(NC(=O)c2cscn2)cc1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.63
PTGDR2 Q9Y5Y4 1/20 0.57
GRM4 Q14833 1/20 0.52
MEN1 O00255 3/20 0.51
ALDH1A1 P00352 2/20 0.51
TP53 P04637 2/20 0.51
KDM4E B2RXH2 2/20 0.50
NR1H4 Q96RI1 5/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HSD17B10 Q99714 1/20 0.49
POLB P06746 1/20 0.48
FFAR1 O14842 2/20 0.48
GLA P06280 1/20 0.46
MITF O75030 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15701041 0.82 PTGDR2 (0.54) KMT2APTGDR2GRM4TP53KDM4E
SCHEMBL15701276 0.82 MAPT (0.55) KMT2APTGDR2GRM4MEN1TP53
SCHEMBL168520 0.82 GRM4 (0.63) PTGDR2GRM4ALDH1A1KDM4ESMN1; SMN2
SCHEMBL1249547 0.80 GRM4 (0.58) KMT2APTGDR2GRM4MEN1ALDH1A1
SCHEMBL15701090 0.79 GRM4 (0.56) KMT2APTGDR2GRM4MEN1TP53
SCHEMBL2430624 0.79 GRM4 (0.56) KMT2APTGDR2GRM4KDM4ESMN1; SMN2
SCHEMBL15070508 0.79 RAB9A (0.59) PTGDR2GRM4ALDH1A1TP53KDM4E
SCHEMBL15701265 0.77 PSEN1 (0.50) KMT2AGRM4MEN1
SCHEMBL28176826 0.77 GRM4 (0.54) KMT2AGRM4MEN1ALDH1A1KDM4E
SCHEMBL2433338 0.77 GRM4 (0.54) PTGDR2GRM4KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2914592-B1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INT (DE) 2017-10-11 EP disclosed
US-9334249-B2 Inhibitors of cytomegalovirus BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 US disclosed
US-9334249-B2 Inhibitors of cytomegalovirus BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 US disclosed
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-08 US disclosed
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-08 US disclosed
WO-2014070979-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS CDKN1A, CCNA1, IFNAR1 KMT2A 617/4885PTGDR2 3848/4885GRM4 4020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.